The endocannabinoid (eCB) system is proposed to act as a “stress buffer” and thus
represents a novel therapeutic target for stress-related psychiatric disorders. Preclinical
data suggests that inhibition of fatty acid amide hydrolase (FAAH), the main degradative
enzyme of the eCB anandamide (AEA), facilitates fear extinction and protects against
the anxiogenic effects of stress. However, no studies have yet assessed whether pharmacological
inhibition of FAAH would produce similar effects in humans.
To read this article in full you will need to make a payment
© 2019 Published by Elsevier Inc.